Safety and enhanced immunostimulatory activity of the DRD2 antagonist ONC201 in advanced solid tumor patients with weekly oral administration.
Mark N SteinJyoti MalhotraRohinton S TaraporeUsha MalhotraAnn W SilkNancy ChanLorna RodriguezJoseph AisnerRobert D AikenTina MayerBruce G HafftyJenna H NewmanSalvatore M AspromontePraveen K BommareddyRicardo EstupinianCharles B ChessonEvita T SadiminShengguo LiDaniel J MedinaTracie SaundersMelissa FrankelAparna KareddulaSherrie DamareElayne WesolowskyChristian GabelWafik S El-DeiryVarun V PrabhuJoshua E AllenMartin StogniewWolfgang OsterJoseph R BertinoSteven K LibuttiJanice M MehnertAndrew ZlozaPublished in: Journal for immunotherapy of cancer (2019)
NCT02250781 (Oral ONC201 in Treating Patients With Advanced Solid Tumors), NCT02324621 (Continuation of Oral ONC201 in Treating Patients With Advanced Solid Tumors).
Keyphrases